ClinicalTrials.Veeva

Menu

Assessment of Sedation Depth Using Processed EEG in ICU Patients With ARDS Receiving Neuromuscular Blockade: A Prospective Observational Study"

T

Tepecik Training and Research Hospital

Status

Completed

Conditions

Sedation Complication
Anesthesia Awareness
Acute Respiratory Distress Syndrome Due to COVID-19

Treatments

Procedure: Depth of sedation monitoring

Study type

Observational

Funder types

Other

Identifiers

NCT06337877
pEEG ARDS

Details and patient eligibility

About

"In intensive care units, therapeutic paralysis has been a routine treatment method for many years in a select group of patients. Sufficient and appropriate sedation in patients undergoing therapeutic paralysis is crucial to prevent awareness and reduce the risk of excessive sedation. Both inadequate and excessive sedation levels can be highly detrimental to the patient. Clinical assessment may not always provide accurate information regarding sedation depth. Recently, the frequency and workload of therapeutic paralysis treatment in intensive care units have increased due to COVID-19 pneumonia. Therefore, the investigators believe that inadequate sedation may be common in these patients. Processed electroencephalogram parameters such as bispectral index or patient state index (PSI), routinely used in operating rooms and intensive care units, are commonly used to indicate sedation depth. In this study, the investigators aimed to determine sedation levels in patients during paralysis, assess the prevalence of inadequate or excessive sedation, and observe the doses of sedatives and analgesics used."

Enrollment

52 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • "Patients aged 18 years and older who have received continuous neuromuscular blocking agents for at least 24 hours."

Exclusion criteria

  1. Patients under 18 years of age,
  2. pregnant individuals
  3. trauma patients,
  4. intracerebral pathology
  5. major bleeding
  6. central nervous system diseases,
  7. pre-existing poor neurological condition before admission to the intensive care unit,
  8. inability to document continuous neuromuscular blocking agent infusion for at least 24 hours."

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems